2016 Archived Content
OVERVIEW | DOWNLOAD BROCHURE | SPEAKERS | SHORT COURSES

SC20: TRANSLATING PRECLINICAL DATA IN THE RATIONAL DESIGN OF CANCER COMBINATION THERAPIES

Monday, March 7 | 8:00 – 11:00 am


This workshop will focus on the practical aspects of designing first-in-man combination trials, using preclinical data to provide a means for choosing schedules, optimizing drug ratios and escalation schemes. The methodologies presented will integrate hypothesis-driven in vivo pharmacology with in silico modeling as an analytical methodology.

This workshop will focus on the practical aspects of designing first-in-man combination trials, using preclinical data to provide a means for choosing schedules, optimizing drug ratios and escalation schemes. The methodologies presented will integrate hypothesis-driven in vivo pharmacology with in silico modeling as an analytical methodology

  • Why synergy doesn’t help in the design of clinically relevant therapies.
  • How to design efficient preclinical combination studies to support early clinical development.
  • When and how to address the question of therapeutic potential for a combination in development.

 

 INSTRUCTOR:


Arijit ChakravartyArijit Chakravarty, Ph.D., Director, Modeling & Simulation (DMPK), Takeda Pharmaceutical International Co.

Arijit is the Director of the Modeling & Simulation (M&S) function at Takeda Pharmaceuticals International Co., Cambridge, MA. He has a Ph.D. in Biochemistry from Dartmouth College, and a Bachelor's in Pharmacy and a Master's in Biological Science from the Birla Institute of Technology and Science, Pilani, India. Prior to his current role, Arijit has worked in other roles at Takeda (formerly Millennium), as a computational biologist, as a group leader and biomarker team leader in the in vivo pharmacology group, and in a translational group, where he led cell biology and pharmacology teams, and served as the discovery project leader for seven programs. He has contributed directly to around fifty drug discovery and development programs in multiple therapeutic areas, from target identification to discovery and early clinical development. Arijit has spoken at more than thirty conferences and invited seminars, published over thirty peer-reviewed articles and book chapters, and over fifty abstracts.

 

Back To Short Courses